⏳ Fetching live dividend data...
Home › Calculator › FNA Dividend Calculator 2026
Paragon 28, Inc. · NYSE
Price: $13.09 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in FNA → $130.9K in 10 years · $221.78/month
Paragon 28, Inc. is a medical device company specializing in the development, manufacturing, and global distribution of advanced surgical systems tailored for foot and ankle procedures. Its comprehensive product portfolio encompasses a wide array of solutions: Plating Systems: This includes the Gorilla plating series, offering specific solutions for Lisfranc injuries, Lapidus procedures, lateral column corrections, calcaneus slides, and naviculocuneiform (NC) fusions. Complementary products like Baby Gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates, as well as Silverback plating systems, are also available. Precision Guidance Technology: The company provides sophisticated guidance systems to enhance accuracy in various operations, such as fusion procedures for bunion deformities, first tarsometatarsal arthrodesis, metatarsal osteotomy for bunion correction, medial column beaming for Charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. Screw Systems: Paragon 28 offers robust screw systems, including the Monster, Mini Monster, and Joust beaming lines, which are critical for applications like bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, and fracture repair. Joint Replacement Solutions: Their offerings extend to total ankle replacement with the APEX 3D systems, alongside total talus spacers designed to replace the talus bone that links the leg and foot. Bunion/Hallux Valgus Correction Systems: Specifically for bunion management, the company provides nail systems such as the Phantom intramedullary nail systems, targeting severe hallux valgus cases. Orthobiologics: A substantial part of their product line comprises various orthobiologics, including bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix. They also feature PRESERVE bone graft systems for homologous applications. Ancillary Products: The company further supplies soft tissue fixation systems, titanium sprayed polyetheretherketone (PEEK) implants, nitinol staple systems, stabilization solutions, and specialized curved instruments. Paragon 28 distributes its products to hospitals and ambulatory surgery centers through an established network of both direct sales representatives and stocking distributors. Founded in 2010, the company maintains its corporate headquarters in Englewood, Colorado.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open FNA position with:
Real after-tax yield depends on where you live and how you hold FNA.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 15.28% | 12.48% | $1,528 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 12.99% | 10.19% | $1,299 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 12.22% | 9.42% | $1,222 / yr |
| 🇬🇧 UK ISA | 0% | 15.28% | 12.48% | $1,528 / yr |
| 🇬🇧 UK Taxable | 8.75% | 13.94% | 11.14% | $1,394 / yr |
| 🇨🇦 TFSA | 0% | 15.28% | 12.48% | $1,528 / yr |
| 🇨🇦 CA Taxable | 25% | 11.46% | 8.66% | $1,146 / yr |
| 🇦🇺 Super (pension) | 15% | 12.99% | 10.19% | $1,299 / yr |
| 🇦🇺 AU Taxable | 30% | 10.70% | 7.90% | $1,070 / yr |
| 🇩🇪 DE Taxable | 26.375% | 11.25% | 8.45% | $1,125 / yr |
| 🇫🇷 FR Taxable | 30% | 10.70% | 7.90% | $1,070 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
FNA pays quarterly — 4 times per year. Next ex-div: TBD.
How FNA compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for FNA sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| D-Return | 2025-04-21 | 203,134 | $13.00 | $2.64M | ||
| D-Return | 2025-04-21 | 20,014 | — | — | ||
| D-Return | 2025-04-21 | 42,113 | $13.00 | $547.5K | ||
| D-Return | 2025-04-21 | 45,035 | $13.00 | $585.5K | ||
| D-Return | 2025-04-21 | 250,000 | $6.60 | $1.65M | ||
| D-Return | 2025-04-21 | 40,216 | $13.00 | $522.8K | ||
| D-Return | 2025-04-21 | 47,347 | $13.00 | $615.5K | ||
| D-Return | 2025-04-21 | 575,320 | $13.00 | $7.48M | ||
| D-Return | 2025-04-21 | 27,588 | — | — | ||
| D-Return | 2025-04-21 | 50,000 | $1.20 | $60.0K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Revenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the FNA dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Paragon 28, Inc. (FNA) is currently trading at $13.09, 38% below its 52-week high. The current dividend yield is 15.28% based on an annual payout of $2.00 per share.
Paragon 28, Inc. (FNA) is a healthcare stock currently trading at $13.09 with a dividend yield of 15.28%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →